[The combined therapy of intervention, operation and biology in patients with middle-advanced renal cell carcinoma].
OBJECTIVE
To observe the effect of the combined therapy of intervention, operation and biology in patients with middle-advanced renal cell carcinoma.


METHODS
Combined therapy was used in 52 cases as combined care groups and the single operational therapy was used in 50 cases as control group. Compare their resection rates, surgical risks and 3, 5 years survival rates.


RESULTS
In the combined care group, the excision rate was 100%, the average amount of blood transfusion during the operation was 280 ml, the average operation time was 100 minutes, and the 3, 5 years survival rates were 73% and 50%; While in the control group, the results were 90%, 396 ml, 130 minutes, 55% and 27% respectively. There were significant differences between 2 groups (P < 0.05).


CONCLUSIONS
Combined therapy could elevate resection rates and 3, 5 years survival rates and decrease surgical risks.
Song
Xi-shuang
XS
Department of Urology, the First Affiliated Hospital of Dalian Medical University, Dalian 116011, China.
He
Zhong-zhou
ZZ
Yin
Ji-bin
JB
Zhang
Ren-ke
RK
Che
Xiang-yu
XY
Wang
Jian-bo
JB
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D004621:Embolization, Therapeutic; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007680:Kidney Neoplasms / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D015996:Survival Rate
D019496:Cancer Vaccines